Analyst Reco. CureVac N.V.

Equities

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-24 pm EDT			5-day change	1st Jan Change
2.51 ^USD	-2.71%		-2.33%	-40.38%

Apr. 24	CureVac Begins Early Stage Portion of Investigational Vaccine Trial	MT
Apr. 24	CureVac Hires New Chief Business Officer	MT

Kempen Upgrades CureVac to Buy From Neutral, Price Target is $10	Dec. 22	MT
CUREVAC : An untrimmed pipeline becomes costly	Nov. 29
CUREVAC : Unchanged cash drain	Nov. 28
CUREVAC : A missed opportunity	23-08-21
CUREVAC : Higher losses expected in future	23-07-25
CUREVAC : Some glimpse of positive pipeline developments	23-06-21
SVB Securities Initiates CureVac at Outperform With $13 Price Target	23-06-08	MT
CUREVAC : Runway prolonged	23-05-30
CUREVAC : One big point despite many misses	23-05-02
JMP Securities Adjusts Price Target on CureVac to $24 From $34, Maintains Outperform Rating	23-04-26	MT
CUREVAC : Everything hangs on the decision of the new CEO	23-03-16
UBS Upgrades CureVac to Buy From Neutral, Adjusts Price Target to $18 From $8	23-01-19	MT
CUREVAC : UBS raises its recommendation to Buy	23-01-19	ZD
Health Care Down Sharply on Rate-Sensitive Sector Bias -- Health Care Roundup	23-01-09	DJ
Jefferies Upgrades CureVac to Buy From Hold	23-01-09	MT
CUREVAC : Berenberg reaffirms its Buy rating	23-01-06	ZD
UBS Initiates Coverage on CureVac With Neutral Rating, $8 Price Target	22-12-20	MT
JMP Securities Adjusts Price Target on CureVac to $34 From $37, Maintains Market Outperform Rating	22-11-17	MT
Berenberg Bank Adjusts CureVac Price Target to $22 From $45, Maintains Buy Rating	22-11-17	MT
Roche’s Alzheimer’s failure has sector-wide implications	22-11-14

No results for this search

CUREVAC : An untrimmed pipeline becomes costly

November 29, 2023 at 02:56 am EST